🔎 Trials Near Me

Home › Cancer (all types) › Tennessee › Nashville

Cancer (all types) clinical trials in Nashville, TN

65 studies for Cancer (all types) are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study of ASP3082 in Adults With Advanced Solid Tumors

RecruitingPhase 1
  • Vanderbilt University Medical Center, Nashville
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05382559

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

RecruitingPhase 3
  • SCRI Oncology Partners, Nashville
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07566156

A Study of PHN-012 in Patients With Advanced Solid Tumors

RecruitingPhase 1
  • PHN-012-001 Site, Nashville
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07127874

Registry Study for Radiation Therapy Outcomes

RecruitingObservational study
  • Tennessee Oncology Proton Center, Franklin · 17 mi away
All ages · All sexes · Updated Sep 29, 2026 · NCT01255748

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

RecruitingObservational study
  • Vanderbilt University Medical Center, Nashville
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

RecruitingPhase 1
  • GSK Investigational Site, Nashville
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07277270

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

RecruitingObservational study
  • Vanderbilt University Medical Center, Nashville
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

RecruitingPhase 2/3
  • Henry-Joyce Cancer Clinic, Nashville
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06989437

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

RecruitingPhase 1
  • Sarah Cannon Cancer Institute, Nashville
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06150157

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

RecruitingPhase 3
  • Sarah Cannon Research Institute, Nashville
  • United States Oncology Regulatory Affairs Corporate Office, Nashville
Ages 18 to 100 · All sexes · Updated Sep 25, 2026 · NCT05920356

A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

RecruitingPhase 1
  • SCRI Oncology Partners, Nashville
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07612176

A Study of JNJ-87890387 for Advanced Solid Tumors

RecruitingPhase 1
  • Sarah Cannon Research Institute, Nashville
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06178614

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

RecruitingPhase 3
  • Vanderbilt University Medical Center, Nashville
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06901531

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

RecruitingPhase 3
  • Quetzal Site 12, Nashville
Ages 18 to 71 · All sexes · Updated Sep 23, 2026 · NCT07504458

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

RecruitingPhase 3
  • SCRI Oncology Partners /ID# 279779, Nashville
  • Vanderbilt University Medical Center /ID# 280169, Nashville
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07365241

Pan Tumor Rollover Study

RecruitingPhase 2
  • Tennesse Oncology, Nashville
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03899155

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

RecruitingPhase 3
  • SCRI Oncology Partners ( Site 7000), Nashville
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07405164

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

RecruitingPhase 2
  • Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

RecruitingPhase 1/2
  • Sarah Cannon Research Institue, Nashville
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

RecruitingPhase 2/3
  • Sarah Cannon Research Inst, Nashville
All ages · All sexes · Updated Sep 18, 2026 · NCT03435796

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

RecruitingPhase 1/2
  • GSK Investigational Site, Nashville
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07213609

A Phase 1/1b Study of IAM1363 in HER2 Cancers

RecruitingPhase 1
  • SCRI Oncology Partners, Nashville
  • Vanderbilt Ingram Cancer Center, Nashville
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06253871

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

RecruitingPhase 1
  • Sarah Cannon Research Center, Nashville
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06440005

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

RecruitingPhase 1/2
  • SCRI Oncology Partners, Nashville
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05386108

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

RecruitingPhase 3
  • Research Site, Nashville
Ages 18 to 130 · All sexes · Updated Sep 8, 2026 · NCT07647328

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

RecruitingPhase 3
  • Tennessee Oncology, Nashville
  • USO - US Oncology Research Network, Nashville
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

RecruitingObservational study
  • Vanderbilt University, Nashville
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06163534

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

RecruitingPhase 3
  • Tennessee Oncology PLLC - Chattanooga, Nashville
  • Tennessee Oncology, PLLC, Nashville
  • Vanderbilt University Medical Center, Nashville
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06252649

Project: Every Child for Younger Patients With Cancer

RecruitingObservational study
  • The Children's Hospital at TriStar Centennial, Nashville
  • Vanderbilt University/Ingram Cancer Center, Nashville
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244

FOG-001 in Locally Advanced or Metastatic Solid Tumors

RecruitingPhase 1/2
  • Sarah Cannon Research Institute, Nashville
  • Vanderbilt Ingram Cancer Center, Nashville
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

RecruitingPhase 1/2
  • Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

RecruitingPhase 3
  • Vanderbilt Breast Center at One Hundred Oaks, Nashville
  • Vanderbilt University/Ingram Cancer Center, Nashville
  • Vanderbilt-Ingram Cancer Center at Franklin, Franklin · 17 mi away
  • and 1 more
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

RecruitingPhase 1
  • SCRI Oncology Partners, Nashville
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT06657144

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

RecruitingPhase 1/2
  • Sara Cannon Research Institute Tennessee, Nashville
Ages 12 and older · All sexes · Updated Jul 14, 2026 · NCT05533697

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

RecruitingPhase 1
  • Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05650632

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

RecruitingPhase 1/2
  • Sarah Cannon Research Institute, Nashville
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

RecruitingPhase 2
  • Vanderbilt University, Ingram Cancer Center, Nashville
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

RecruitingPhase 1/2
  • Tennessee Oncology, Nashville
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT06162221

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

RecruitingEarly phase 1
  • Vanderbilt University Medical Center, Nashville
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT07493447

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

RecruitingPhase 1
  • GSK Investigational Site, Nashville
Ages 18 and older · All sexes · Updated Jun 25, 2026 · NCT06431594

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

RecruitingPhase 1
  • Sarah Cannon, SCRI Oncology Partners, Nashville
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT04678648

CT-95 in Advanced Cancers Associated With Mesothelin Expression

RecruitingPhase 1
  • Context Investigational Site, Nashville
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT06756035

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

RecruitingPhase 1/2
  • Vanderbilt University Medical Center, Nashville
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT06051695

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

RecruitingPhase 1
  • Research Site, Nashville
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT06835569

Galleri® in the Medicare Population.

RecruitingHealthy volunteers welcome
  • HCA Healthcare Centennial, Nashville
  • HCA Healthcare Nashville, Nashville
  • HCA Healthcare Brentwood, Brentwood · 9 mi away
Ages 50 and older · All sexes · Updated May 22, 2026 · NCT05673018

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

RecruitingPhase 1
  • GSK Investigational Site, Nashville
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT06551142

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

RecruitingPhase 1
  • Vanderbilt University Medical Center, Nashville
Ages 18 and older · All sexes · Updated May 11, 2026 · NCT07217028

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

RecruitingPhase 1
  • Sarah Cannon Research Institute, Nashville
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT05954312

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

RecruitingEarly phase 1
  • Vanderbilt University Medical Center, Nashville
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT06828588

High-Resolution PET-CT Imaging for Surgical Margin Visualization

Recruiting
  • Vanderbilt University Medical Center, Nashville
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT06915454

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

RecruitingPhase 1
  • SCRI Oncology Partners, Nashville
  • Vanderbilt-Ingram Cancer Center, Nashville
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06326411

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

RecruitingPhase 1
  • SCRI Oncology Partners, Nashville
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT05948865

Suprachoroidal Administration in Subjects With Metastases to the Choroid

RecruitingPhase 2
  • Tennessee Retina, PC, Nashville
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT06643884

A Study of YL242 in Subjects With Advanced Solid Tumors

RecruitingPhase 1/2
  • US-205, Nashville
Ages 18 and older · All sexes · Updated Dec 24, 2025 · NCT07197827

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

RecruitingPhase 1
  • Vanderbilt-Ingram Cancer Center, Nashville
Ages 18 and older · All sexes · Updated Dec 19, 2025 · NCT05270213

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

RecruitingPhase 1
  • Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
Ages 18 to 99 · All sexes · Updated Dec 3, 2025 · NCT07021898

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RecruitingObservational study
  • Massive Bio SYNERGY-AI site, Nashville
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

Inherited CAncer REgistry

RecruitingObservational studyHealthy volunteers welcome
  • Vanderbilt-Ingram Cancer Center, Nashville
Ages 18 and older · All sexes · Updated Sep 16, 2025 · NCT03231891

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

RecruitingPhase 1/2
  • Sarah Cannon Research Institute, Nashville
Ages 18 and older · All sexes · Updated May 18, 2025 · NCT05970497

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

RecruitingPhase 1/2
  • SCRI Oncology Partners, Nashville
Ages 18 and older · All sexes · Updated May 1, 2025 · NCT04503265

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

RecruitingPhase 1/2
  • Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Ages 18 and older · All sexes · Updated Feb 13, 2025 · NCT05669430

Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up

RecruitingObservational study
  • Provision CARES Proton Therapy Nashville, Franklin · 17 mi away
All ages · All sexes · Updated Feb 8, 2023 · NCT02070328

About Cancer (all types)

If you or someone you love has been diagnosed with cancer, learn about diagnosis, treatment, risk factors, coping and much more.

More about Cancer (all types) on MedlinePlus

Cancer (all types) trials in other cities

Other studies in Nashville

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.